首页> 外文期刊>Der Pharmacia Lettre >Comparison of lasuna with atorvastatin and its investigation of hydrogen sulfide release in obese and/or hyperlipidemic cases
【24h】

Comparison of lasuna with atorvastatin and its investigation of hydrogen sulfide release in obese and/or hyperlipidemic cases

机译:肥胖症和/或高脂血症病例中LASAU与阿托伐他汀的比较及其硫化氢释放的研究

获取原文
           

摘要

Medicinal Use of garlic is established since ages in different forms against various disorders. However, its efficacy against a marketed, well-known allopathy therapy is hardly been dealt with. The aim of this study was to use a standardized market preparation of Garlic, Himalaya’s herbal preparation, Lasuna capsules available in the market as Over the counter product, for comparison with the standard groups of Atorvastatin (10 mg) as well as a third combined group (comprising of both formulations) in Hyperlipidemic and/or Obese patients. A 12 weeks nonrandomized, open, parallel group clinical study was carried out to confirm these findings in patients having Hyperlipidemia and/or Obesity. Recently, hydrogen sulfide has emerged as a potential novel gaseous molecule with a promising role in protective mechanism against damage to the heart. The consumption of garlic is inversely correlated with the progression of cardiovascular disease, although the responsible mechanisms remain unclear. A study showed that human RBCs convert garlic-derived organic polysulfides into hydrogen sulfide (H2S), an endogenous cardioprotective vascular cell signaling molecule [1]. One of the study objectives was to study the release of hydrogen sulfide, the novel gastro-transmitter from this standardized, marketed formulation. The study also aimed to establish safety of the garlic formulation versus the statin therapy alone and in combination and whether the side-effects observed are tolerable. The statistical evaluation of data showed that lasuna was unable to deliver statistically significant results in a span of treatment for three months. However, it can be prescribed as a supporting regimen with Atorvastatin therapy which may be helpful in preventing an increase in dose of allopathy drug. Also, Lasuna capsules showed a marked increase in the levels of hydrogen sulfide from baseline to three months treatment, thus confirming release of H2S inside the body probably after metabolism of its active constituents.
机译:自从以各种形式对抗各种疾病的年龄以来,就建立了大蒜的药用用途。然而,其针对市售的,众所周知的同种疗法的功效几乎没有得到解决。这项研究的目的是使用标准化的大蒜市场制剂,喜马拉雅草药制剂,Lasuna胶囊作为非处方产品在市场上出售,以与阿托伐他汀(10毫克)的标准组以及第三个联合组进行比较(包括两种配方)在高脂血症和/或肥胖患者中。进行了一项为期12周的非随机,开放,平行组临床研究,以证实高脂血症和/或肥胖症患者的这些发现。近来,硫化氢已成为一种潜在的新型气态分子,在防止心脏损伤的保护机制中起着有希望的作用。大蒜的摄入与心血管疾病的发展呈负相关,尽管其作用机理尚不清楚。一项研究表明,人类红细胞将大蒜来源的有机多硫化物转化为硫化氢(H2S),即一种内源性的心脏保护性血管细胞信号分子[1]。研究的目标之一是研究从这种标准化的市售配方中释放出的新型气体递质硫化氢。该研究还旨在确定大蒜制剂相对于单独或联合他汀类药物治疗的安全性,以及所观察到的副作用是否可以忍受。数据的统计评估表明,在三个月的治疗期间,lasuna无法提供统计学上显着的结果。但是,可以将其处方为阿托伐他汀疗法的支持方案,这可能有助于防止同种疗法药物剂量的增加。此外,从基线到治疗三个月,Lasuna胶囊的硫化氢水平也显着增加,从而证实了H2S可能在其活性成分代谢后释放到体内。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号